Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista do Instituto de Medicina Tropical de São Paulo |
Texto Completo: | https://www.revistas.usp.br/rimtsp/article/view/197664 |
Resumo: | The B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and discuss potential explanations for the infection recurrence. A prospective, non-interventional follow-up of discharged patients who had SARS-CoV-2 infections by the Delta variant in Guangdong, China, from May 2021 to June 2021 was conducted. The subjects were asked to complete a physical health examination and undergo nucleic acid testing and antibody detection for the laboratory diagnosis of COVID-19. In total, 20.33% (25/123) of patients exhibited recurrent positive results after discharge. All patients with infection recurrence were asymptomatic and showed no abnormalities in the pulmonary computed tomography. The time from discharge to the recurrent positive testing was usually between 1-33 days, with a mean time of 9.36 days. The cycle threshold from the real-time polymerase chain reaction assay that detected the recurrence of positivity ranged from 27.48 to 39.00, with an average of 35.30. The proportion of vaccination in the non-recurrent group was higher than that in the recurrently positive group (26% vs. 4%; χ2 = 7.902; P < 0.05). Two months after discharge, the most common symptom was hair loss and 59.6% of patients had no long-term symptoms at all. It is possible for the Delta variant SARS-CoV-2 patients after discharge to show recurrent positive results of nucleic acid detection; however, there is a low risk of continuous community transmission. Both, the physical and mental quality of life of discharged patients were significantly affected. Our results suggest that it makes sense to implement mass vaccination against the Delta variant of SARS-CoV-2. |
id |
IMT-1_3b276fc20e8b917b6edcc33b1a54ae96 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/197664 |
network_acronym_str |
IMT-1 |
network_name_str |
Revista do Instituto de Medicina Tropical de São Paulo |
repository_id_str |
|
spelling |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, ChinaCOVID-19SARS-CoV-2Follow-up surveyDelta variantThe B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and discuss potential explanations for the infection recurrence. A prospective, non-interventional follow-up of discharged patients who had SARS-CoV-2 infections by the Delta variant in Guangdong, China, from May 2021 to June 2021 was conducted. The subjects were asked to complete a physical health examination and undergo nucleic acid testing and antibody detection for the laboratory diagnosis of COVID-19. In total, 20.33% (25/123) of patients exhibited recurrent positive results after discharge. All patients with infection recurrence were asymptomatic and showed no abnormalities in the pulmonary computed tomography. The time from discharge to the recurrent positive testing was usually between 1-33 days, with a mean time of 9.36 days. The cycle threshold from the real-time polymerase chain reaction assay that detected the recurrence of positivity ranged from 27.48 to 39.00, with an average of 35.30. The proportion of vaccination in the non-recurrent group was higher than that in the recurrently positive group (26% vs. 4%; χ2 = 7.902; P < 0.05). Two months after discharge, the most common symptom was hair loss and 59.6% of patients had no long-term symptoms at all. It is possible for the Delta variant SARS-CoV-2 patients after discharge to show recurrent positive results of nucleic acid detection; however, there is a low risk of continuous community transmission. Both, the physical and mental quality of life of discharged patients were significantly affected. Our results suggest that it makes sense to implement mass vaccination against the Delta variant of SARS-CoV-2.Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo2022-05-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/rimtsp/article/view/19766410.1590/S1678-9946202264031Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e31Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e31Revista do Instituto de Medicina Tropical de São Paulo; v. 64 (2022); e311678-99460036-4665reponame:Revista do Instituto de Medicina Tropical de São Pauloinstname:Instituto de Medicina Tropical (IMT)instacron:IMTenghttps://www.revistas.usp.br/rimtsp/article/view/197664/181898Copyright (c) 2022 Qilin Wu, Chang Wang, Qinlong Jing, Jianyun Lu, Boheng Liang, Lan Liu, Jinyi Wu, Qing Yu, Xilong Deng, Zhoubin Zhanghttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessWu, Qilin Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin 2022-10-10T13:01:46Zoai:revistas.usp.br:article/197664Revistahttp://www.revistas.usp.br/rimtsp/indexPUBhttps://www.revistas.usp.br/rimtsp/oai||revimtsp@usp.br1678-99460036-4665opendoar:2022-12-13T16:53:16.923159Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)true |
dc.title.none.fl_str_mv |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
spellingShingle |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China Wu, Qilin COVID-19 SARS-CoV-2 Follow-up survey Delta variant |
title_short |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_full |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_fullStr |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_full_unstemmed |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_sort |
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
author |
Wu, Qilin |
author_facet |
Wu, Qilin Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin |
author_role |
author |
author2 |
Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Wu, Qilin Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin |
dc.subject.por.fl_str_mv |
COVID-19 SARS-CoV-2 Follow-up survey Delta variant |
topic |
COVID-19 SARS-CoV-2 Follow-up survey Delta variant |
description |
The B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and discuss potential explanations for the infection recurrence. A prospective, non-interventional follow-up of discharged patients who had SARS-CoV-2 infections by the Delta variant in Guangdong, China, from May 2021 to June 2021 was conducted. The subjects were asked to complete a physical health examination and undergo nucleic acid testing and antibody detection for the laboratory diagnosis of COVID-19. In total, 20.33% (25/123) of patients exhibited recurrent positive results after discharge. All patients with infection recurrence were asymptomatic and showed no abnormalities in the pulmonary computed tomography. The time from discharge to the recurrent positive testing was usually between 1-33 days, with a mean time of 9.36 days. The cycle threshold from the real-time polymerase chain reaction assay that detected the recurrence of positivity ranged from 27.48 to 39.00, with an average of 35.30. The proportion of vaccination in the non-recurrent group was higher than that in the recurrently positive group (26% vs. 4%; χ2 = 7.902; P < 0.05). Two months after discharge, the most common symptom was hair loss and 59.6% of patients had no long-term symptoms at all. It is possible for the Delta variant SARS-CoV-2 patients after discharge to show recurrent positive results of nucleic acid detection; however, there is a low risk of continuous community transmission. Both, the physical and mental quality of life of discharged patients were significantly affected. Our results suggest that it makes sense to implement mass vaccination against the Delta variant of SARS-CoV-2. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-05-16 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/rimtsp/article/view/197664 10.1590/S1678-9946202264031 |
url |
https://www.revistas.usp.br/rimtsp/article/view/197664 |
identifier_str_mv |
10.1590/S1678-9946202264031 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/rimtsp/article/view/197664/181898 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo |
publisher.none.fl_str_mv |
Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo |
dc.source.none.fl_str_mv |
Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e31 Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e31 Revista do Instituto de Medicina Tropical de São Paulo; v. 64 (2022); e31 1678-9946 0036-4665 reponame:Revista do Instituto de Medicina Tropical de São Paulo instname:Instituto de Medicina Tropical (IMT) instacron:IMT |
instname_str |
Instituto de Medicina Tropical (IMT) |
instacron_str |
IMT |
institution |
IMT |
reponame_str |
Revista do Instituto de Medicina Tropical de São Paulo |
collection |
Revista do Instituto de Medicina Tropical de São Paulo |
repository.name.fl_str_mv |
Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT) |
repository.mail.fl_str_mv |
||revimtsp@usp.br |
_version_ |
1798951655006273536 |